President Joe Biden’s nominee to run the US Department of Health & Human Services is reviving fears in industry about executive action to invoke so-called “march in” rights: seeking to suspend patent rights on medicines that rely in part on taxpayer funded research as a mechanism to control costs.
Trump’s Legacy Versus ‘March In’ Rights
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.